ASPAGNII(TM) – INDIGENEOUS TUMOUR ANTIGEN

  • June 6, 2021
  • Posted by: OptimizeIAS Team
  • Category: DPN Topics
No Comments

 

 

ASPAGNII(TM) – INDIGENEOUS TUMOUR ANTIGEN

Subject: Science & tech

Context: DBT-NII Receives Trademark for India’s First Indigenous Tumour Antigen SPAG9.

Concept:

  • India’s first indigenous tumour antigen SPAG9 was discovered by Dr Anil Suri in 1998 who is heading the Cancer Research Program at the New Delhi-based National Institute of Immunology (NII), an Autonomous Institute of Department of Biotechnology (DBT).
  • In a recent development, the SPAG9 antigen has received the trademark ASPAGNIITM.
  • Currently, ASPAGNIITM is being used in dendritic cell (DC) based immunotherapy in cervical, ovarian cancer and will also be used in breast cancer.

Immunotherapy

  • Immunotherapy is a new approach that exploits the body’s inner capability to put up a fight against cancer.
  • With this approach, either the immune system is given a boost, or the T cells are “trained’’ to identify recalcitrant cancer cells and kill them.
ASPAGNII(TM) - INDIGENEOUS TUMOUR ANTIGEN Science and tech